Verde Resources, Inc. filed a Form 8-K on November 17, 2026, disclosing the appointment of Michelle Yanez as Chief Financial Officer, effective November 16, 2026, along with the terms of her employment agreement.
Key Highlights
- New CFO appointed: Michelle Yanez was appointed Chief Financial Officer by the board of directors on November 13, 2026, with an effective date of November 16, 2026.
- Prior CFO transitions role: Sherina Chui, the prior chief financial officer, moves to the role of Senior Financial Controller commencing November 16, 2026.
- Base salary: Pursuant to the CFO Agreement, Ms. Yanez will receive a base salary of $225,000 per annum.
- Stock grant: Ms. Yanez will receive a one-time grant of the company's common stock valued at $25,000.
- Prior services compensated: The company agreed to pay Ms. Yanez shares of common stock valued at $40,375 for services rendered under a prior services agreement through November 15, 2026.
- Extensive industry background: According to the filing, Ms. Yanez has over 25 years of experience in public and privately held biotech, pharmaceutical, and life science companies.
- Agreement term: The CFO Agreement has an initial term of two years but is at-will, with either party able to terminate at any time.
Verde Resources Names New Chief Financial Officer With Life Sciences Background
Verde Resources, Inc., a Nevada-incorporated company headquartered at 7800 Forsyth Blvd., Suite 850, St. Louis, Missouri, filed a current report disclosing a leadership change in its finance function. According to the filing, the board of directors appointed Michelle Yanez as Chief Financial Officer on November 13, 2026, with the role taking effect on November 16, 2026. The company's securities registered pursuant to Section 12(b) of the Act are listed as "None" in the filing's registered-securities table, with no trading symbol or exchange indicated.
The filing states that Ms. Yanez had been serving as a consultant to the company on capital markets, finance, and SEC compliance matters since March 2026 under a services agreement dated March 1, 2026. That services agreement was automatically terminated upon the effective date of the new CFO Agreement. Ms. Yanez is also Co-Founder and CFO of Santander Pharma Consulting, a privately held life sciences consulting firm, since February 2024, and previously served as CFO of MIRA Pharmaceuticals (Nasdaq: MIRA) from April 2023 to June 2025, and as CFO of Telomir Pharmaceuticals (Nasdaq: TELO) from June 2024 to June 2025, according to the filing. She also serves as a non-employee director of Inhibitor Therapeutics, Inc. (OTCQB: INTI) since December 2022.
Under the CFO Agreement dated November 14, 2026, Ms. Yanez is eligible for annual performance-based cash bonuses and equity incentive awards, subject to board discretion and approval, and may participate in employee benefit plans including medical and dental insurance. The filing notes that in the event of termination without cause or resignation for good reason, Ms. Yanez will be entitled to certain severance benefits as defined in the CFO Agreement. Ms. Yanez agreed to confidentiality, non-solicitation, non-competition, and other standard covenants. The filing was signed by Jack Wong, Chief Executive Officer, on November 17, 2026.
What Was Disclosed
Verde Resources, Inc. reported the appointment of Michelle Yanez as CFO, effective November 16, 2026, the transition of prior CFO Sherina Chui to Senior Financial Controller, and the key terms of Ms. Yanez's employment agreement, including salary, stock grants, and severance provisions.




Please wait processing your request...